Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identification
Matteo Ferro(European Institute of Oncology), Daniela Terracciano(Federico II University Hospital), Octavian Sabin Tătaru(Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș), Francesco Lasorsa(University of Bari Aldo Moro), Bernardo Rocco(Università Cattolica del Sacro Cuore), Michele Catellani(European Institute of Oncology), Felice Crocetto(University of Naples Federico II), Gian Maria Busetto(Sapienza University of Rome), Martina Maggi(Policlinico Umberto I), Evelina La Civita(Federico II University Hospital), Biagio Barone(Ospedale San Paolo), A. Brescia(Istituti di Ricovero e Cura a Carattere Scientifico), Ugo Giovanni Falagario(Ospedali Riuniti di Foggia), Francesco Del Giudice(Sapienza University of Rome), Giuseppe Lucarelli(University of Bari Aldo Moro)
Cited by 10
Related Papers
Male Oxidative Stress Infertility (MOSI): Proposed Terminology and Clinical Practice Guidelines for Management of Idiopathic Male Infertility
|The World Journal of Men s Health|2019|468
European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era
|European Urology|2020|313
Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection
|European Urology|2019|212
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
|International Journal of Molecular Sciences|2022|190